PLGA microspheres containing bee venom proteins for preventive immunotherapy

Area of Science:

• Immunology
• Materials Science
• Pharmacology

Background:

• Bee venom (BV) allergy poses significant health risks, including anaphylaxis and death.
• Current venom immunotherapy (VIT) involves numerous injections over years, leading to poor patient compliance.
• There is a need for improved delivery systems to enhance VIT efficacy and patient adherence.

Purpose of the Study:

• To characterize poly(lactic-co-glycolic acid) (PLGA) microsphere formulations containing bee venom (BV) proteins for improved VIT.
• To evaluate the potential of these microspheres as a strategy to replace multiple injections in traditional VIT.

Main Methods:

• Preparation and characterization of different MS-PLGA formulations encapsulating BV proteins.
• Analysis using physical and biochemical methods to assess encapsulation efficiency and protein release.
• Evaluation of conformational changes and immunological recognition of released BV.

Main Results:

• Achieved encapsulation efficiencies ranging from 49% to 75% for BV-loaded microspheres.
• Observed a triphasic BV release profile, with MS-PLGA 34kDa-COOH showing a low initial burst (20%) and sustained release.
• Demonstrated minimal conformational changes in released BV, maintaining its immunological recognizability.

Conclusions:

• MS-PLGA microspheres represent a promising strategy for a reduced injection schedule in BV venom immunotherapy (VIT).
• The MS-PLGA 34kDa-COOH formulation is particularly suitable for VIT due to its controlled release characteristics.
• This novel approach could significantly improve patient compliance and treatment outcomes for bee venom allergy.